News

Article

Recipharm Enters Long-Term Supply Agreement with Tillotts Pharma AG

The agreement comprises technology transfer and commercial manufacturing of Tillotts’ gastroenterology products.

CDMO Recipharm announced that it has entered into a long-term supply agreement with Tillotts Pharma AG.

This collaboration comprises technology transfer and commercial manufacturing of Tillotts’ gastroenterology products-Entocort and Asacol for the treatment of Crohn’s disease and ulcerative colitis, as well as a total shared investment of EUR3.5 million (approximately $3.92 million) across Recipharm’s network for this business.

Recipharm will also be involved in the commercial-scale development of Tillotts’ ulcerative colitis drug TP05, which is undergoing clinical evaluation.

Recipharm will provide advanced pellet coating technology for controlled release from its facility in Pessac, France, tablet and capsule manufacturing including final packaging from its facility in Fontaine, France, and bottle filling from its site in Lisbon, Portugal. This agreement is part of Recipharm’s strategy to provide full-service offering to its customers.

Source: Recipharm

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Related Videos
A global supply chain map, visualizing the complex network of transportation routes and distribution centers | Image Credit: © venusvi - stock.adobe.com
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Jason Waite, International Trade Expert, Alston & Bird
Simona Guidi, Associate Director, ProPharma
Tore Bergsteiner
Behind the Headlines, Episode 20: CAR-T Milestones, Abbvie and Eli Lilly M&A Moves, and More
Related Content